Studying liver tissue in urea cycle disorders
Part of Brain & nervous system, Digestive system, Genetic & congenital, Hormones & metabolism clinical trials.
This study looks at liver tissue (under a microscope) in people with urea cycle disorders to better understand liver changes from the condition. It may help clinicians learn what to watch for and how to manage liver health, especially around liver biopsy or transplant.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a confirmed or strongly suspected urea cycle disorder (confirmed by enzyme tests, DNA testing, or blood/urine metabolite tests).
- You have had a liver transplant and/or liver biopsy in the past, or you have one planned.
- You can provide access to the biopsy or transplant tissue and the pathology report (microscope results).
- The study team can obtain the pathology report and the actual tissue samples/slides for review.
- Your liver disease is not due to another known cause such as chronic viral hepatitis, autoimmune liver disease, short gut/small bowel syndrome, alcohol-related liver disease, or special nutrition-related liver injury.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies blood and other measurable signs (biomarkers) that may reflect brain injury after certain inherited metabolic conditions. Results may help doctors better detect and understand brain effects from these illnesses, especially episodes that affect the brain.
This study evaluates how people with urea cycle disorders perform during a driving task. It may help researchers understand if the condition affects driving ability.
This study tests an investigational drug called KRRO-121. It is first tested in healthy volunteers to check safety, and then in patients with urea cycle disorder (a condition where the body can't remove ammonia properly) to see if it helps.
This trial tests a new medicine called LNP.UCD.ABE that aims to fix a specific genetic change causing a severe urea cycle disorder. It uses a technique called base editing to correct the gene mutation, which may help your body break down ammonia better.
This study follows people who have (or might have) NAGS deficiency and who are taking Carbaglu to treat it. The goal is to better track safety and health outcomes over time.
This study looks at adults who have known or possible problems in the digestive system or liver. It may help patients by offering structured evaluation and follow-up for their condition.
Hear when a new Ornithine Transcarbamylase Deficiency trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.